Squarepoint Ops LLC Ocuphire Pharma, Inc. Transaction History

Squarepoint Ops LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.59 - $3.64 $68,168 - $95,804	26,320 Added 75.56%	61,152 $184,000
Q2 2023 Aug 14, 2023	BUY	$3.63 - $6.38 $126,440 - $222,228	34,832 New	34,832 $151,000
Q1 2022 May 16, 2022	SELL	$2.75 - $4.39 $29,301 - $46,775	-10,655 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.4 - $5.19 $36,227 - $55,299	10,655 New	10,655 $40,000
Q3 2021 Nov 15, 2021	SELL	$3.84 - $5.38 $74,476 - $104,345	-19,395 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$4.24 - $6.57 $38,287 - $59,327	9,030 Added 87.12%	19,395 $102,000
Q1 2021 May 17, 2021	SELL	$5.7 - $13.31 $52,479 - $122,545	-9,207 Reduced 47.04%	10,365 $60,000
Q4 2020 Feb 16, 2021	BUY	$3.76 - $8.8 $73,590 - $172,233	19,572 New	19,572 $127,000

2.61M

14.1K

800

Ticker OCUP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,579,800
Market Cap $20.2M
Description
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.